A Phase 3 interventional study of Educational Intervention and Gabapentin in Malignant Head and Neck Neoplasm, Mucositis and Radiation-Induced Disorder, sponsored by Vanderbilt-Ingram Cancer Center. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Vanderbilt-Ingram Cancer Center · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Head and Neck Neoplasms by Vanderbilt-Ingram Cancer Center — 5 open to participants now, 5 under way, none of them phase 3. Head and Neck Neoplasms · Vanderbilt-Ingram Cancer Center.
Among the 30 studies in Head and Neck Neoplasms by Vanderbilt-Ingram Cancer Center, this one has the largest enrollment of the 16 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 3, and was the 22nd registered.
2,716 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.
Browse Head and Neck Neoplasms studies →5 of the 30 studies in Head and Neck Neoplasms by Vanderbilt-Ingram Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is above the median of 46 across 2,036 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 36 across the 16 interventional studies, 77 across the 14 observational. Of the 25 that completed or were terminated, 6 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vanderbilt-Ingram Cancer Center is the lead sponsor of 223 studies on the registry; 32 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 19 (83%) have results posted.
1 of the studies in Head and Neck Neoplasms by Vanderbilt-Ingram Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06915454Vanderbilt-Ingram Cancer CenterHigh-Resolution PET-CT Imaging for Surgical Margin Visualization | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Head and Neck Neoplasms by Vanderbilt-Ingram Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized phase III trial studies how well gabapentin plus standard of care work compares to standard of care without Gabapentin in preventing inflammation of the mucous membranes (mucositis) in patients with stage III-IV head and neck cancer that are undergoing primary or subsequent (adjuvant) chemoradiation therapy. Radiation therapy to the head and neck may cause a burn involving the inside of the mouth, throat, and nasal passages, resulting in pain. Gabapentin may help prevent (or minimize) pain associated with radiation-induced mucositis in patients with head and neck cancer.
Primary Objectives:
Secondary Objectives:
Exploratory Objectives:
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Standard of Care (usual care) - Patients receive consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of chemoradiation treatment to review foundations of oral care and pain management.
ARM II: Standard of Care plus Gabapentin - Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin orally (PO) three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
After completion of study treatment, patients are followed up monthly for 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
Other: Educational Intervention · Other: Pain Therapy · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Drug: Oxycodone/Acetaminophen · Drug: Hydrocodone/Acetaminophen · Drug: Fentanyl · Drug: Ibuprofen · Drug: Magic Mouthwash
Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
Other: Educational Intervention · Drug: Gabapentin · Other: Pain Therapy · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Drug: Oxycodone/Acetaminophen · Drug: Hydrocodone/Acetaminophen · Drug: Fentanyl · Drug: Ibuprofen · Drug: Magic Mouthwash
Undergo oral care and pain management education session
Also known as: Education for Intervention
Given PO
Also known as: Gralise, Neurontin, 1-(aminomethyl) cyclohexaneacetic Acid, 60142-96-3,
Receive usual oral health care
Also known as: Analgesia, Pain Control, Pain Management, Pain
Ancillary studies
Also known as: Quality of Life Assessment
Ancillary studies
Drug page: Oxycodone-acetaminophenStudies of Oxycodone-acetaminophenOxycodone-acetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Analgesia
Also known as: Percocet
Analgesia
Also known as: Lortab, Vicodin
Transdermal Analgesia
Also known as: Duragesic
NSAID Analgesia
Also known as: Motrin, Advil
Oral Solution to treat mucositis
Also known as: Miracle Mouthwash, First-Mouthwash BLM, First-BXN Mouthwash
Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))
The pain subscale is composed of 4 items of the Vanderbilt Head and Neck Symptom Survey. The subscale score was calculated by taking the first non-negative principle component of the 4 items. The scale was scores range from 0 to 10 with 10 representing the worst pain.
Time frame: Up to 3 months post-treatment
Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)
Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \< 0.05). Frequency distributions will summarize the safety outcome.
Time frame: Up to 3 months post-treatment
Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)
Pain severity will be correlated with frequency and severity of general systemic symptoms. Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \< 0.05). Baseline pain scores will be included as a covariate in the analyses of the outcome. The General Symptom Survey is a ten item patient reported outcome measure and outcomes were averaged as there is only one item per symptom category. 0 represented no presence of the symptom with a score of 10 representing the most severe symptom.
Time frame: Up to 3 months post-treatment
Participants were enrolled at Vanderbilt Medical Center in Nashville, TN from July 2015 to May 2019. 79 participants were recruited and 8 of those withdrew.
| Milestone | Arm II Standard of Care Plus Gabapentin | Arm I Standard of Care |
|---|---|---|
| Started | 41 | 38 |
| Completed | 32 | 30 |
| Not completed | 9 | 8 |
| Withdrew: Not completing surveys | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Disease progression | 3 | 0 |
| Withdrew: Improper completion of survey | 1 | 1 |
| Withdrew: Not eligible | 0 | 1 |
The pain subscale is composed of 4 items of the Vanderbilt Head and Neck Symptom Survey. The subscale score was calculated by taking the first non-negative principle component of the 4 items. The scale was scores range from 0 to 10 with 10 representing the worst pain.
| score on a scale | Arm I Standard of Care | Arm II Standard of Care Plus Gabapentin |
|---|---|---|
| Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS)) | 4.26 (3.98 to 5.16) | 3.68 (2.04 to 3.68) |
Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \< 0.05). Frequency distributions will summarize the safety outcome.
| Participants | Arm I Standard of Care | Arm II Standard of Care Plus Gabapentin |
|---|---|---|
| Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0) | 0 | 0 |
Pain severity will be correlated with frequency and severity of general systemic symptoms. Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \< 0.05). Baseline pain scores will be included as a covariate in the analyses of the outcome. The General Symptom Survey is a ten item patient reported outcome measure and outcomes were averaged as there is only one item per symptom category. 0 represented no presence of the symptom with a score of 10 representing the most severe symptom.
| score on a scale | Arm I Standard of Care | Arm II Standard of Care Plus Gabapentin |
|---|---|---|
| Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form) | 1.91 (0.73 to 3.56) | 1.23 (0.45 to 2.79) |
Collected over Approximately 3 months after completion of treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I Standard of Care | 0/38 (0%) | 0/38 (0%) | 0/38 (0%) |
| Arm II Standard of Care Plus Gabapentin | 0/41 (0%) | 0/41 (0%) | 2/41 (4.9%) |
| Event | Arm I Standard of Care | Arm II Standard of Care Plus Gabapentin |
|---|---|---|
| FatigueGeneral disorders | 0/38 | 2/41 |
| Age, Categorical(Participants) | Arm I Standard of Care | Arm II Standard of Care Plus Gabapentin | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 32 | 34 | 66 |
| >=65 years | 6 | 7 | 13 |
| Age, Continuous(Years) | Arm I Standard of Care | Arm II Standard of Care Plus Gabapentin | Total |
|---|---|---|---|
| Median | 61.5 (54.75 to 66.25) | 61 (52 to 66) | 61 (53 to 66) |
| Sex: Female, Male(Participants) | Arm I Standard of Care | Arm II Standard of Care Plus Gabapentin | Total |
|---|---|---|---|
| Female | 12 | 14 | 26 |
| Male | 26 | 27 | 53 |
| Race (NIH/OMB)(Participants) | Arm I Standard of Care | Arm II Standard of Care Plus Gabapentin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 33 | 39 | 72 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Region of Enrollment(participants) | Arm I Standard of Care | Arm II Standard of Care Plus Gabapentin | Total |
|---|---|---|---|
| United States | 38 | 41 | 79 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jul 2015, a primary completion of Sep 2019 and a completion of Jan 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Vanderbilt-Ingram Cancer Center →